Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer

Disease Characteristics: * Patients with a documented histologic or cytologic diagnosis of a pancreatic malignancy * Patients with recurrent, advanced and/or metastatic disease, who have either failed standard therapy or are not eligible for any alternate therapies of higher therapeutic priority. * Patients with at least one identified (confirmed) and measureable tumor site. Prior/Concurrent Therapy: * Surgery: Patients are excluded if they have had major surgery either during or within four weeks prior to study entry. * Chemotherapy: Patients must have failed standard therapy or are not eligible for any alternate therapies of higher therapeutic priority. * Biologic Therapy: Patients who have received a chimeric, CDR-grafted (humanized), or human IgG will be eligible provided pre-study evaluations demonstrate no significant reactivity with hMN14 IgG (i.e., HAHA) * Radiotherapy: No prior radiotherapy within four weeks of study entry. No prior external beam irradiation to a field that includes more than 30% of the red marrow. No prior radiation to maximal tolerable levels for any critical organ (e.g., 3,000 cGy for the liver; 2,000 cGy for the lungs and kidneys). * Other: Any experimental therapy (i.e., drugs, biologics, procedures) for the primary malignancy, either during or within four weeks prior to study entry. Patient Characteristics/Inclusion Criteria: * Performance Status: Patients with a Karnofsky performance status \> 70% (or equivalent, ECOG 0-1) and an expected survival rate of at least 3 months * Hematopoietic: Hemoglobin \> 10g/dL; WBC \> 3000 per mm3; Granulocyte count \> 1500 per mm3; platelet count \> 100,000 per mm3 * Hepatic: Total bilirubin \< 1.5 times the institutional upper limit of normal (IULN); AST or ALT \< 2 X IULN * Renal: Creatinine \< IULN * Cardiovascular: Patients with LVEF \>/= 50% by required MUGA/2D-ECHO study * Pulmonary: Patients with DF and FEV1 \>/= 60 % by required Pulmonary Function Tests * Gastrointestinal:Patients with severe anorexia or other related symptomology are excluded * Central Nervous System: Patient with known metastatic disease to the CNS are excluded * Other: Patients who have had a prior imaging study with a murine antibody may be included. Patients agreeing to use a medically effective method of contraception during and for a period of three months after the treatment period. A pregnancy test will be preformed on each premenopausal female of childbearing potential immediately prior to entry into the study. Patients able to understand and give written informed consent.